SEC 13F Intelligence

Managers / Q1 2019 · view latest →

Endurant Capital Management LP

CIK 0001633055 · 66 BOVET ROAD, SUITE 353, SAN MATEO, CA, 94402 · 650-539-5905

Reported Value
$253M
Q1 2019
Positions
70
Filings on Record
24
2019–present window
Filed
May 15, 2019
original filing

Summary

Endurant Capital Management LP reported $253M in U.S.-listed holdings across 70 positions for Q1 2019.

Its largest position, BMY, represents 5.5% of the portfolio.

Compared with Q4 2018, the fund opened 43 new positions and exited 22.

Portfolio Metrics

Turnover
+52.4%
vs prior filed quarter
Top-10 Concentration
+43.3%
share of reported value
Largest Position
+5.5%
Bristol Myers Squibb
New / Exited
43 / 22
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $189MQ4 ’18Q1 ’19: $253MQ2 ’19: $254MQ3 ’19: $279MQ3 ’19Q4 ’19: $317MQ1 ’20: $221MQ2 ’20: $1.8BQ2 ’20Q3 ’20: $338MQ4 ’20: $277MQ1 ’21: $384MQ1 ’21Q2 ’21: $364MQ3 ’21: $439MQ4 ’21: $414MQ4 ’21Q1 ’22: $380MQ2 ’22: $285MQ3 ’22: $307MQ3 ’22Q4 ’22: $246MQ1 ’23: $195MQ2 ’23: $115MQ2 ’23Q3 ’23: $111MQ4 ’23: $17MQ1 ’24: $0Q1 ’24filingsflow.com

Portfolio Composition

By security type
Common Stock: 66.6%Other: 19.4%ETP: 6.8%US DOMESTIC: 3.7%ADR: 3.5%
  • Common Stock · 66.6% · $169M
  • Other · 19.4% · $49M
  • ETP · 6.8% · $17M
  • US DOMESTIC · 3.7% · $9M
  • ADR · 3.5% · $9M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2018 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
VCRAUSDVOCERA COMMUNICATIONS INCNEW+390.9K390.9K+$12M$12M
SPDR S&P 500 ETF TRNEW+37.1K37.1K+$10M$10M
GILDGILEAD SCIENCES INCNEW+155.8K155.8K+$10M$10M
TAKEDA PHARMACEUTICAL CO LTDNEW+437.4K437.4K+$9M$9M
HCAHCA HEALTHCARE INCNEW+60.1K60.1K+$8M$8M
ATRCATRICURE INCNEW+266.6K266.6K+$7M$7M
LABORATORY CORP AMER HLDGSNEW+44.9K44.9K+$7M$7M
219AVEDRO INCNEW+442.0K442.0K+$5M$5M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2019

47 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1BMYBRISTOL MYERS SQUIBB COhistory →COM5.49%$14M291.3K
2IINUSDINTRICON CORPhistory →COM5.48%$14M552.5K
3ICON PLCSHS5.45%$14M100.9K
4VCRAUSDVOCERA COMMUNICATIONS INChistory →COM4.89%$12M390.9K
5CICIGNA CORP NEWhistory →COM4.26%$11M67.0K
6GILDGILEAD SCIENCES INChistory →COM4.00%$10M155.8K
7ZBHZIMMER BIOMET HLDGS INChistory →COM3.90%$10M77.3K
8TAKEDA PHARMACEUTICAL CO LTDSPONSORED ADS3.52%$9M437.4K
9FLUIDIGM CORP DELNOTE 2.750% 2/03.24%$8M8.76M
10HCAHCA HEALTHCARE INChistory →COM3.10%$8M60.1K
11WRIGHT MED GROUP N VORD SHS3.08%$8M247.4K
12RCMEURR1 RCM INChistory →COM2.87%$7M750.4K
13ATRCATRICURE INChistory →COM2.82%$7M266.6K
14ABGAMERISOURCEBERGEN CORPhistory →COM2.78%$7M88.5K
15LABORATORY CORP AMER HLDGSCOM NEW2.71%$7M44.9K
16219AVEDRO INChistory →COM2.14%$5M442.0K
17EVHEVOLENT HEALTH INChistory →CL A2.08%$5M418.7K
18LIVANOVA PLCSHS1.63%$4M42.3K
19IRTCIRHYTHM TECHNOLOGIES INChistory →COM1.49%$4M50.3K
20THCTENET HEALTHCARE CORPhistory →COM NEW1.39%$4M121.8K
21ACRSACLARIS THERAPEUTICS INChistory →COM1.29%$3M545.7K
22MEDTRONIC PLCSHS1.28%$3M35.6K
23CNCCENTENE CORP DELhistory →COM1.15%$3M55.0K
24TMOTHERMO FISHER SCIENTIFIC INChistory →COM1.14%$3M10.5K
25OCULOCULAR THERAPEUTIX INChistory →COM1.12%$3M716.1K
26LUMINEX CORP DELCOM1.10%$3M121.0K
27NEON THERAPEUTICS INCCOM1.09%$3M425.3K
28LQDALIQUIDIA TECHNOLOGIES INChistory →COM1.06%$3M235.3K
29ALLERGAN PLCSHS1.06%$3M18.3K
30ELVANTHEM INChistory →COM1.03%$3M9.1K
31BHCBAUSCH HEALTH COS INChistory →COM1.02%$3M104.3K
32VCELVERICEL CORPCOM0.85%$2M123.1K
33XENTEURINTERSECT ENT INCCOM0.83%$2M65.6K
34KRYSKRYSTAL BIOTECH INCCOM0.80%$2M61.2K
35AXOVANT SCIENCES LTDCOM0.76%$2M1.45M
36ABTABBOTT LABSCOM0.76%$2M24.0K
37AFWALIGN TECHNOLOGY INCCOM0.74%$2M6.6K
38MRNSUSDMARINUS PHARMACEUTICALS INCCOM0.72%$2M437.3K
39VKTXVIKING THERAPEUTICS INCCOM0.70%$2M178.4K
40OXFORD IMMUNOTEC GLOBAL PLCORD SHS0.70%$2M102.6K
41ABBVABBVIE INCCOM0.69%$2M21.7K
42SRPTSAREPTA THERAPEUTICS INCCOM0.68%$2M14.4K
43XRAYDENTSPLY SIRONA INCCOM0.57%$1M29.0K
44HWAYEURTIVITY HEALTH INCCOM0.54%$1M77.9K
45SENSEONICS HLDGS INCNOTE 5.250% 2/00.42%$1M1.00M
46AG8AGILENT TECHNOLOGIES INCCOM0.40%$1M12.6K
47OSMOTICA PHARMACEUTICALS PLCSHS0.40%$1M279.6K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2024$01May 7, 202413F-HRchanges · EDGAR ↗
Q4 2023$17M25Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$111M43Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$115M34Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$195M50May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$246M55Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$307M49Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$285M50Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$380M63May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$414M68Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$439M53Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$364M57Aug 27, 2021RESTATEMENTchanges · EDGAR ↗
Q1 2021$384M61May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$277M52Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$338M60Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.8B56Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$221M51May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$317M54Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$279M49Nov 25, 2019RESTATEMENTchanges · EDGAR ↗
Q2 2019$254M50Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$253M70May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$189M48Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.